Predica Diagnostics

Executive Summary

Predica Diagnostics is a Dutch biotechnology startup founded in 2021 and headquartered in Amsterdam. The company is developing proprietary biomarker-based diagnostic tests for the early detection and monitoring of cancer, with a mission to reduce overdiagnosis and overtreatment by providing objective, personalized treatment suggestions. Leveraging a unique biomarker analysis platform, Predica aims to address critical gaps in oncology diagnostics, particularly in identifying aggressive versus indolent tumors. The company's approach targets a significant unmet need in cancer care, where early and accurate detection can dramatically improve patient outcomes and reduce healthcare costs. Predica's technology has the potential to be applied across multiple cancer types, starting with prostate and lung cancer. Based in the Netherlands—a hub for life sciences innovation—the company benefits from a strong research ecosystem. As a young, pre-revenue entity, Predica's success hinges on advancing its pipeline, securing partnerships, and obtaining regulatory approvals. The combination of a novel biomarker platform and a clear clinical focus positions Predica as a compelling player in the precision diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026First Clinical Validation Study Results50% success
• Q2 2027CE Mark Submission for Lead Diagnostic Test30% success